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Abstract
Importance and Objective: Prior influenza infection is a risk factor for invasive meningococcal disease. Quantifying the
fraction of meningococcal disease attributable to influenza could improve understanding of viral-bacterial interaction and
indicate additional health benefits to influenza immunization.
Design, Setting and Participants: A time series analysis of the association of influenza and meningococcal disease using
hospitalizations in 9 states from 1989–2009 included in the State Inpatient Databases from the Agency for Healthcare
Research and Quality and the proportion of positive influenza tests by subtype reported to the Centers for Disease Control.
The model accounts for the autocorrelation of meningococcal disease and influenza between weeks, temporal trends, co-
circulating respiratory syncytial virus, and seasonality. The influenza-subtype-attributable fraction was estimated using the
model coefficients. We analyzed the synchrony of seasonal peaks in hospitalizations for influenza, respiratory syncytial virus,
and meningococcal disease.
Results and Conclusions: In 19 of 20 seasons, influenza peaked#2 weeks before meningococcal disease, and peaks were
highly correlated in time (r=0.95; P ,.001). H3N2 and H1N1 peaks were highly synchronized with meningococcal disease
while pandemic H1N1, B, and respiratory syncytial virus were not. Over 20 years, 12.8% (95% CI, 9.1–15.0) of meningococcal
disease can be attributable to influenza in the preceding weeks with H3N2 accounting for 5.2% (95% CI, 3.0–6.5), H1N1 4.3%
(95% CI, 2.6–5.6), B 3.0% (95% CI, 0.8–4.9) and pH1N1 0.2% (95% CI, 0–0.4). During the height of influenza season, weekly
attributable fractions reach 59%. While vaccination against meningococcal disease is the most important prevention
strategy, influenza vaccination could provide further protection, particularly in young children where the meningococcal
disease vaccine is not recommended or protective against the most common serogroup.
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Introduction
Neisseria meningitidis is a leading cause of meningitis and sepsis
in young children and adolescents in the United States, with an
estimated incidence of 0.53 cases of invasive meningococcal
disease (MD) per 100,00 population, and 1525 cases occurring
annually between 1998 and 2007 [1,2]. It is an important
pathogen globally, with incidence estimates varying geographically
up to the exceptionally high estimated 1000 cases per 100,000 in
the African ‘‘meningitis belt’’ [3].
Reports of MD outbreaks in closed communities following
influenza epidemics hint at a possible causal relationship, but
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e107486direct evidence of antecedent infection with influenza among MD
patients is difficult to obtain in most circumstances, though it has
been found as a risk factor in certain epidemic settings [4–8].
Influenza may no longer be detectable in an individual whose MD
was caused by co-infection with influenza, as the virus is rapidly
cleared from the nasopharynx within 4 - 10 days of initial
symptom onset [9,10], which is comparable to the incubation
period of MD [11,12]. Evidence of a causal link for influenza
predisposing to MD comes from animal studies, disease records of
past pandemics, and time series regression models [13–17], whose
conclusions as with all observational analyses can be considered
causal only if confounding factors are adequately accounted for.
Previous studies of MD and influenza time series have relied on
small numbers of reported MD cases over short time periods and
broad categorizations of influenza activity to detect an association
between MD and influenza. A study in France over 5 years
showed that the incidence of MD in a given week correlated with
influenza counts in the preceding 5 weeks and that MD cases were
more clinically severe during or up to 2 months after influenza
outbreaks [16]. Periods of influenza activity correlated with MD
across all age groups in Denmark [17]. A Canadian study provided
further evidence using both regression models and a case-crossover
design [18].
Influenza could facilitate meningococcal colonization and
subsequent invasive disease by several biological mechanisms.
Influenza could affect meningococcus transmission by facilitating
dispersion of the bacteria or by increasing a person’s risk of
becoming a carrier when exposed [14]. In mice, influenza-induced
immune dysregulation increases susceptibility to invasive MD
[19,20]. Likewise, influenza A neuraminidase increases the
adherence of meningococcus to epithelial cells, a necessary step
for meningococcus to colonize the nasopharynx [21,22]. Influenza
B, by contrast, does not seem to increase meningococcal adhesion
[23].
Given the evidence that influenza infection increases MD risk,
we investigated the synchrony of these diseases and quantified the
amount of hospitalized MD that is attributable to influenza. This is
the largest study to analyze the effects of circulating influenza
subtypes, co-circulating respiratory syncytial virus (RSV), and
patient age on this association and the only study that quantifies
the association using the attributable fraction (AF). We used a
large hospitalization database covering 20 influenza seasons in 9
states to explore the role of each of these factors in modifying the
fraction of MD attributable to influenza.
Methods
Study Population and Data Sources
The study population consisted of all residents in the nine states
that continuously contributed data since 1989 to the State
Inpatient Databases (SID), a part of the Healthcare Cost and
Utilization Project (HCUP) sponsored by the Agency for
Healthcare Research and Quality (AHRQ) [24]. Since the
investigators of this study had no interaction with patients and
received no identifiable private information as part of this study,
we were not required to obtain ethics approval or individual
patient consent by the Harvard School of Public Health
institutional review board under the United States Department
of Health and Human Services’ regulations on human subjects.
The SID contains all hospitalizations from community hospitals
in the participating state and provides the primary and all
secondary discharge diagnoses. The nine states (AZ, CA, CO, IA,
IL, MA, NJ, WA, WI) were combined to create an aggregate age-
stratified dataset by week of admission. We studied the period
from January 1, 1989 to November 21, 2009, which represents 20
complete influenza seasons (August 1 through July 31). We
removed the final six weeks of 2009 in the dataset to avoid any
effects of reporting delays. Working in collaboration with AHRQ,
weekly counts of hospitalizations due to MD (ICD-9-CM=036.0-
036.9), influenza (ICD-9-CM=487.0-487.9, 488.1) (FLU), or
RSV (ICD-9-CM=079.6, 466.11, 480.1) were provided from
the SID. We describe our methods for handling missing data in
Section S1 of Text S1.
To determine whether influenza subtypes differed in their
relationship with MD, we obtained the weekly proportion of
positive tests by influenza subtype (B, A/H1N1, A/H3N2 or 2009
pandemic A/H1N1 (pH1N1)) from the Centers for Disease
Control and Prevention (CDC) [25]. Testing begins mid-
September and ends in May. We used the aggregate national
samples to represent the subtype contribution in our nine states, as
publicly-available state-level information was not available.
Although the relative importance of influenza subtypes can vary
somewhat across the United States within a mild season, the most
severe seasons (where the putative interaction between influenza
and MD would be most salient) are geographically homogeneous
(www.cdc.gov/flu). The weekly proportions of positive tests by
subtype were multiplied by the weekly count of influenza
hospitalizations (FLUt) to give a subtype attributable estimate of
the weekly number of influenza hospitalizations caused by each
subtype (SAIHt).
Analytic Approach
Two sets of analyses were performed to assess the relationship of
MD to FLU and RSV. The first assessed the synchrony of timing
of peak hospitalizations for MD with FLU and RSV. The second
used regression modeling to estimate the fraction of MD
attributable to influenza in aggregate, by subtype, patient age,
and co-circulating RSV.
Synchrony of peak hospitalizations. To compare the
timing of the peak in FLU or RSV hospitalizations with MD
each season, each time series was smoothed to create a 5-week
moving average. If there was a tie for the peak hospitalizations in a
season, all tied weeks were included. The synchrony was also
explored between influenza subtypes and MD. Given that the
subtype-attributable hospitalizations were a product of the viral
and hospitalization data, we chose to use only seasons where each
subtype was circulating at a meaningful level. This resulted in a
season being excluded in the correlation analysis if there were
fewer than 75 estimated hospitalizations at the peak for a given
subtype. Pearson correlation coefficients were calculated compar-
ing the timing of the peak in each of the 20 seasons.
Modeling meningococcal disease. To estimate the fraction
of MD attributable to seasonal influenza, we developed a
regression model that accounts for the autocorrelation of MD
between weeks, the underlying changes in both MD and FLU
incidence over time, and seasonality. We have demonstrated that
incidence rates of MD using multiple robust datasets has declined
substantially since our study period began, while incidence of
hospitalizations due to influenza towards the end of our study were
higher (Section S2 of Text S1). To account for these changes, MD
counts were modeled as a function of season (using sinusoids),
trend (using linear and quadratic time terms), autoregressive terms
with MD lagged 1–3 weeks, SAIH lagged 1 week, and terms to
allow influenza to have a changing effect on MD over time (effect
modification).
Unique aspects of our modeling approach, explained further in
Section S3 of Text S1, include: the use of a negative binomial
generalized linear model with an identity link, autoregressive terms
Meningococcal Disease and Influenza in the US
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annually to reflect changing populations or risk levels, and the use
of Legendre polynomials to prevent collinearity of the time
covariates [26]. Comparable models were created for MD in 3 age
categories as the main outcome (,5, 5–24, and.24 years old)
using all age SAIH but for brevity, all further methods will
describe the influenza subtype model.
Estimating the attributable fraction of meningococcal
disease associated with influenza subtypes. We define the
AF to be the fraction of hospitalizations caused by MD that could
be avoided if influenza infection could be prevented. We estimate
the subtype AF based on the coefficients estimated in the model
previously described. The numerator of the AF represents the
expected MD in a hypothetical influenza-free world while
accounting for the autocorrelation of MD generated in the
absence of influenza, minus the observed MD incidence in the
presence of influenza; thus the numerator is the difference in
incidence between a counterfactual influenza-free world and the
observed world. To turn this difference into an attributable
fraction, it is divided by the observed incidence. The inclusion of
autoregressive terms for MD complicates our estimation of the
numerator, as we cannot observe what MD would have been in
previous weeks in the absence of the effect of influenza. To
estimate the AF, we applied the g-formula [27] to generate a
chronologically iterative process whereby expected MD counts are
estimated using the prior three weeks’ estimates for the lagged
autoregressive terms. In the first three weeks when we cannot
estimate the expected MD count, we use the observed MD.
Formally, under the assumption that all common causes of
influenza and MD are appropriately accounted for, the g-formula
provides an expression for the expected MD counts had one
intervened to prevent influenza from occurring in the past. The
AF is described further in Section S3 of Text S1.
We varied the possible time lag between influenza and MD
from 67 weeks, including multiple week lags, and chose the model
with the best fit as determined by Akaike’s Information Criterion.
Our use of an additive rather than multiplicative model allowed an
unbiased estimate of the cumulative AF when multiple subtypes
are included [28] with the result that the overall influenza AF is
the sum of the subtype-specific AF.
RSV was initially modeled using the same time lags as FLU, up
to 7 weeks before. It was modeled independent of influenza and in
models with FLU lagged up to 7 weeks. The best-fitting time lag
was 6 weeks for RSV and 1 week for influenza. With these lags, the
parameter estimates for RSV were negative (b= 20.00176) but
significant (p-value 0.0009) and the model did not fully converge.
As the time lag for RSV decreased, the coefficient became less
negative but increasingly also were not significant. After consid-
ering the results of both the modeling efforts and peak week
analysis, we chose to exclude RSV as a potential contributing
factor to MD and removed it from subsequent models.
We estimated 95% confidence intervals of the AF point estimate
using a wild bootstrap [29,30] where each week is randomly
assigned a weight from an exponential distribution with a mean of
1 but the chronology and serial correlation between weeks is
preserved. The log likelihood in the model is then the product of
the weekly weight times the log likelihood for the negative
binomial model, which essentially reweights the score equation.
For each reweighting, the parameters were estimated by maxi-
mum likelihood and an AF for that random weighting scheme was
estimated. We generated 1000 independent and identically
distributed weights and calculated 1000 AF. The 95% confidence
intervals were calculated with the percentile method, as the
distributions of AF calculated from the 1000 model runs were not
skewed and the mean AF estimate closely approximated the
observed AF [31,32].
In order to assess the impact of unmeasured confounding of the
association between MD and influenza by a year-specific or a
season-specific common cause, we performed two different
permutation tests, described in Section S4 of Text S1.
All statistical analyses were performed using R, Version
2.12.0[33] and the NLMIXED and SURVEYSELECT proce-
dures in SASH Version 9.3 for Windows XP_PRO.
Results
In our 20-year study period, the 9 states in the SID recorded
17,575 MD and 242,520 FLU hospitalizations. We attributed
136,813 influenza hospitalizations to H3N2, 42,989 to influenza B,
25,444 to H1N1 and 24,234 to pH1N1. Influenza hospitalizations
during months without viral testing were not included (n=13,040).
In the 20 seasons analyzed (198921990 to April 15, 2009), the
median peak weeks of FLU and MD were weeks 30.5 and 31,
respectively (third to fourth week in January). The weeks after
April 15, 2009 were treated as a unique season to separate pH1N1
from seasonal influenza. There was no synchrony between MD
and pH1N1. This may have been an artifact of using an
incomplete year or of the unusual seasonality in FLU that year.
The peak in MD for this period was the tail end of the 2008209
season while FLU peaked in the last week of October,
corresponding with the fall wave of pandemic cases, suggesting
we needed the full 2009210 season to observe the MD peak. In all
seasons but one, 199221993, FLU peaked within 2 weeks before
MD; during the 1992293 season, MD peaked 1 week before FLU
(Figure 1A). The peak weeks were highly correlated (r=0.95; P
,.001). This remarkable synchrony of the peak in FLU and MD is
observed whether influenza peaks earlier or later in the season. In
contrast to influenza, RSV was not synchronized with MD
(r=0.07; P =.77) and peaked equally before and after MD.
There was a marked difference in the synchrony of peaks of the
different subtype hospitalizations and MD (Figure 1B). To look at
synchrony only in seasons where each subtype was circulating at a
meaningful level, a season was excluded in the correlation analysis
if there were fewer than 75 hospitalizations at the peak for a given
subtype. This resulted in 16 (H3N2), 7 (H1N1), and 13 (B) seasons
analyzed for correlation. H3N2 (r=0.90; P ,.001) and H1N1
(r=0.92; P =.003) were highly synchronized with MD hospital-
izations while influenza B showed little evidence of an association
(r=0.20; P =.51). During our study period, influenza B was the
dominant strain in only 2 seasons but in those years peaked with
(1990291) or 1 week before MD (1992293). The only season
when H3N2 or H1N1 peaked after MD was 1992293 when B
dominated.
The model of the association of SAIH and MD explained
68.5% of the variability of MD over 20 years (Table 1) and
captured the timing of the peaks in MD quite well (Figure 2). The
model over-predicts MD hospitalizations in the two more severe
A/H3N2-dominant influenza seasons. During the 20 years of our
study, 12.8% (95% CI, 9.1215.0) of MD can be attributable to
FLU in the preceding weeks with H3N2 accounting for 5.2%
(95% CI, 3.026.5), H1N1 4.3% (95% CI, 2.625.6), B 3.0% (95%
CI, 0.824.9) and pH1N1 0.2% (95% CI, 020.4). During the
height of influenza season, AFs reach as high as 59% in a given
week for all influenza and H3N2, 48% for H1N1, 23% for
influenza B and 51% for pH1N1 (Figure 3).
There was little statistical difference between the cumulative AF
for each age group, with 12.9 (95% CI, 8.7215.8), 15.5 (95% CI,
10.6219.0) and 9.2 (95% CI, 4.9212.6) percent of the MD
Meningococcal Disease and Influenza in the US
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Additional discussion of the results by age and geography can be
found in Sections S5 and S6 of Text S1.
After considering the results of both the modeling efforts and
peak week analysis, we chose to exclude RSV as a potential
contributing factor to MD. The best fitting time lag for RSV was 6
weeks but the RSV parameter estimate was negative and the
model did not fully converge (b= 20.00176; P ,.001). As the
time lag for RSV decreased, the coefficient became less negative
but also less significant.
Discussion
Our study adds to the body of evidence suggesting that
influenza infection is a contributing cause of invasive MD, and we
have four major findings: 1) the peak in FLU is highly
synchronized with the peak in MD hospitalizations; 2) a
substantial fraction of MD can be attributed to FLU in the
preceding weeks; 3) there is variability in this association by
influenza subtype and age, but geography has little to no effect in
the areas studied, and 4) RSV is not associated with MD. The
remarkable coherence in timing of peaks in influenza and MD
hospitalizations over twenty seasons, regardless of when the highly
variable influenza season begins, is suggestive of a strong causal
relationship. Influenza is neither a necessary nor sufficient cause of
MD; however, over a twenty-year period, 13% of MD can be
attributed to hospitalizations for seasonal influenza in the
preceding weeks. The strength of the causal inference made here,
as in any observational study, depends on the adequacy of controls
for confounding causes that are associated with the exposure
(influenza) and are causally related to the outcome (MD). In
particular, we have attempted to control for seasonal or other
temporal factors (weather or human behavior, for example) that
might be common causes of MD and influenza, through three
means: inclusion of sinusoidal and trend terms in the regression,
permutation tests to account for uncontrolled seasonal variation,
and the use of synchrony analyses that use variation between years
in seasonal peak timing to avoid confounding by any factor that
shows a consistent seasonal trend.
These findings are consistent with earlier work using time series
containing 1–2% as many MD cases as analyzed here [17,18].
The results of our study differed with previous work on the
contribution of RSV and influenza B to MD. Our findings suggest
that influenza B contributes less to MD than influenza A but it is
still a significant contribution. Others found no association
between influenza B and MD but suggested a lack of statistical
power as a cause [18]. Our results suggest that RSV is not involved
in the causal pathway of developing invasive MD. Two other
studies have looked at the association of RSV with MD and have
found conflicting evidence. One study supports our results and
suggests that RSV is not important in developing MD [34]
whereas another study found evidence of an association with RSV
[18].
The difference in cumulative AF between the subtypes was not
proportional to the relative SAIH contributions to the hospital-
ization burden over the twenty years; 6:2:1:1 for A/H3N2, B,
H1N1 and pH1N1. Since a six-fold higher incidence of H3N2
SAIH exposure does not translate into dramatically higher AF in
our study, it suggests that there is not a fixed relationship between
the number of FLU hospitalizations and the number of MD
hospitalizations, but that this relationship may be modified by
influenza subtypes, perhaps the characteristics of circulating
meningococcal strains, and age [22,23,35]. Using hospitalizations
rather than another indicator of influenza activity as our exposure
has limitations in that the probability of hospitalization given
infection is different among the subtypes [36,37]. In years with
multiple subtypes co-circulating, we likely bias H3N2 towards the
null and B and H1N1 away from the null because we assign
hospitalizations proportional to the percent of positive tests in a
given week regardless of their propensity to cause severe disease
necessitating hospitalization. While there is no perfect count of
influenza infection in a population, we believe our use of influenza
hospitalizations and SAIH is an improvement over solely using
viral surveillance data [18], because viral surveillance data alone,
expressed as a percentage of positive tests, cannot linearly account
Figure 1. Meningococcal disease (MD) annual peak timing
shows strong correlation with peak of influenza (FLU),
especially A/H3N2 and A/H1N1 but not RSV. A We analyzed 20
seasons and defined the week for each season in which FLU, RSV, or MD
had the maximum count as the peak week. The synchrony of the peak
week for FLU, RSV, and MD was compared. FLU (marked by a blue
triangle) peaked 2 weeks or less before MD in all seasons but one. The
peak weeks were highly correlated (r=0.95; P ,.001). In contrast, RSV
(marked by circles) was not synchronized with MD (r=0.07; P =.77)
and peaked equally before and after MD. B Same analysis repeated for
each season and each influenza subtype. Including only seasons with at
least 75 subtype-attributable influenza hospitalizations, we analyzed 16
(H3N2), 7 (H1N1), and 13 (B) seasons for correlation with MD. H3N2
(r=0.90; P ,.001) and H1N1 (r=0.92; P =.003) were highly
synchronized with MD hospitalizations while influenza B showed little
evidence of an association (r=0.20; P =.51). During our study period,
influenza B was the dominant strain in only 2 seasons but in those years
peaked with (1990291) or 1 week before MD (1992293). The only
season when H3N2 or H1N1 peaked after MD was 1992293 when B
dominated.
doi:10.1371/journal.pone.0107486.g001
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has been shown in the UK and US that the percent of tests
submitted that were positive for influenza is a poor proxy for
influenza morbidity or mortality and poorly reflects the timing and
overall severity of an epidemic given changes in viral surveillance
over time (both between and within seasons) [40–43].
The marginal contribution of pH1N1 to MD in our regression
analyses, and lack of temporal synchrony, merits further study with
data from 2010 and later. Such analyses may help to distinguish
among several hypotheses for the weak or absent association seen
here: artifact of the cutoff for data analysis at the end of 2009;
different seasonal factors promoting influenza (which departed
from the normal seasonality during the pandemic) and MD,
Figure 2. Observed MD compared with model-predicted MD. MD counts were modeled in a negative binomial generalized linear model with
an identity link. Independent variables included a sinusoidal term for seasonal variation, linear and quadratic time trends (modeled using Legendre
polynomials), autoregressive terms with MD lagged 123 weeks, SAIH lagged 1 week, and terms to allow influenza to have a changing effect on MD
over time (effect modification).
doi:10.1371/journal.pone.0107486.g002
Figure 3. Weekly fraction of MD attributable to all subtypes together and individual influenza subtypes. Most seasons were dominated
by either influenza A/H1N1 or A/H3N2, with little of the other subtype. Nearly all seasons also showed a smaller contribution from influenza B.
doi:10.1371/journal.pone.0107486.g003
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pH1N1’s tendency to contribute to MD risk.
The study had several limitations. The ecologic design, using
data from 2 independent surveillance systems, makes it impossible
to draw direct causal links between influenza and MD. In an ideal
study design, we would create a large cohort and follow them
prospectively for several years to determine when each person
developed influenza or MD. However, the rarity of MD and the
difficulty in defining an influenza case would require impossibly
large cohorts being sampled frequently for influenza infection.
We also used ICD-9 diagnostic codes from the State Inpatient
Database as proxies for infection and disease incidence. These
codes are neither perfectly sensitive, as some cases will not be
detected, nor perfectly specific, as some cases will be misclassified
as FLU or MD when they are not. If the multiplicative relationship
between true incidence and each proxy remained constant over
the study period, then no error would be introduced by the use of
the proxy. Departures from this ideal relationship will add error to
our estimates.
We used national information on the relative dominance of
each influenza subtype in our regression models, because state-
specific data were not available. Surveillance reports however
indicate that the most severe A/H3N2 seasons, during which the
interaction between influenza and MD is strongest, are spatially
homogeneous (eg 1999–2000 or 2003–4) [44,45]. Further, for our
synchrony analyses we used state-specific data on influenza-
hospitalization rates to estimate the local incidence of disease
activity. As laboratory-based surveillance is strengthened in the US
and elsewhere, our models could be improved by inclusion of
more local proxies of influenza and RSV virus activity.
Our findings have implications for infectious disease control
policy. While vaccination against MD is the most important
prevention strategy, vaccination against influenza could provide
further protection particularly in the youngest and most vulnerable
age group where MD vaccination is not recommended and 13%
of MD is attributable to influenza. Given that current MD
vaccines do not offer complete protection against all serogroups,
including B, one of the three most prevalent causes of invasive
disease in the US [46] and the most common in young children
[1], immunizing against influenza would result in reductions of
MD where MD vaccine cannot. The recent trend toward
increasing childhood influenza vaccination in the US may have
an impact on MD incidence both through direct protection of
influenza-vaccinated persons against influenza which may lead to
MD, and through herd immunity to influenza that may offer
indirect protection to others against influenza infection leading to
MD.
In summary, we found that the age and subtype patterns
evidenced in this epidemiological study reinforce the possibility of
a biological association between influenza and MD and exclude
this association with RSV.
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